Key to Abbreviations |
|
xi | |
Preface |
|
xv | |
Contributors |
|
xvii | |
Section 1 Cancer Treatment |
|
1 | (336) |
|
Introduction to Chemotherapy Drugs |
|
|
2 | (252) |
|
|
31 | (3) |
|
|
34 | (3) |
|
|
37 | (3) |
|
|
40 | (2) |
|
|
42 | (2) |
|
|
44 | (2) |
|
Androgens: testosterone propionate, obfluoxymesterone, obtestolactone |
|
|
46 | (2) |
|
|
48 | (3) |
|
|
51 | (2) |
|
|
53 | (2) |
|
|
55 | (3) |
|
|
58 | (3) |
|
|
61 | (2) |
|
|
63 | (3) |
|
|
66 | (3) |
|
|
69 | (3) |
|
|
72 | (5) |
|
|
77 | (3) |
|
|
80 | (4) |
|
cytarabine, cytosine arabinoside |
|
|
84 | (4) |
|
cytarabine liposome injection |
|
|
88 | (2) |
|
|
90 | (3) |
|
|
93 | (3) |
|
daunorubicin citrate liposome injection |
|
|
96 | (4) |
|
daunorubicin hydrochloride |
|
|
100 | (3) |
|
|
103 | (5) |
|
doxorubicin hydrochloride |
|
|
108 | (3) |
|
doxorubicin hydrochloride liposome injection |
|
|
111 | (6) |
|
|
117 | (2) |
|
Estrogens: diethylstilbestrol, diethylstilbestrol diphosphate, ethinyl estradiol, conjugated estrogen, chlorotrianisene |
|
|
119 | (3) |
|
|
122 | (3) |
|
|
125 | (3) |
|
|
128 | (2) |
|
|
130 | (3) |
|
|
133 | (1) |
|
|
134 | (4) |
|
|
138 | (2) |
|
|
140 | (3) |
|
|
143 | (2) |
|
|
145 | (2) |
|
|
147 | (3) |
|
|
150 | (5) |
|
|
155 | (3) |
|
|
158 | (2) |
|
|
160 | (2) |
|
|
162 | (2) |
|
mechlorethamine hydrochloride |
|
|
164 | (3) |
|
|
167 | (4) |
|
|
171 | (2) |
|
|
173 | (2) |
|
|
175 | (4) |
|
|
179 | (2) |
|
|
181 | (3) |
|
|
184 | (2) |
|
|
186 | (3) |
|
|
189 | (1) |
|
|
190 | (2) |
|
|
192 | (4) |
|
|
196 | (2) |
|
|
198 | (3) |
|
|
201 | (4) |
|
|
205 | (2) |
|
polifeprosan 20 with carmustine (BCNU) implant |
|
|
207 | (3) |
|
procarbazine hydrochloride |
|
|
210 | (3) |
|
Progestational Agents: medroxyprogesterone acetate, magestrol acetate |
|
|
213 | (2) |
|
|
215 | (3) |
|
|
218 | (2) |
|
|
220 | (3) |
|
|
223 | (3) |
|
|
226 | (3) |
|
|
229 | (2) |
|
|
231 | (2) |
|
topotecan hydrochloride for injection |
|
|
233 | (2) |
|
|
235 | (2) |
|
|
237 | (3) |
|
|
240 | (1) |
|
|
241 | (3) |
|
|
244 | (3) |
|
|
247 | (3) |
|
|
250 | (4) |
|
Biologic Response Modifier Therapy |
|
|
254 | (40) |
|
|
256 | (2) |
|
|
258 | (2) |
|
|
260 | (4) |
|
|
264 | (4) |
|
|
268 | (1) |
|
|
269 | (1) |
|
|
270 | (3) |
|
megakaryocyte growth and development factor |
|
|
273 | (1) |
|
|
274 | (3) |
|
|
277 | (1) |
|
|
278 | (4) |
|
|
282 | (2) |
|
tositumomab, I131 tositumomab |
|
|
284 | (3) |
|
|
287 | (3) |
|
|
290 | (4) |
|
Antineoplastic Treatment Agonists: Radiosensitizers, Chemosensitizers, and Chemical Adjuncts |
|
|
294 | (11) |
|
chromic phosphate P32 suspension |
|
|
295 | (3) |
|
|
298 | (1) |
|
|
299 | (1) |
|
|
300 | (2) |
|
|
302 | (3) |
|
|
305 | (7) |
|
|
305 | (3) |
|
dexrazoxane for injection |
|
|
308 | (2) |
|
|
310 | (2) |
|
Cancer Treatment Strategies: New Frontiers |
|
|
312 | (25) |
|
|
318 | (3) |
|
|
321 | (2) |
|
|
323 | (5) |
|
|
328 | (4) |
|
|
332 | (5) |
Section 2 Symptom Management |
|
337 | (180) |
|
|
338 | (80) |
|
|
348 | (1) |
|
|
348 | (2) |
|
aspirin, acetylsalicylic acid |
|
|
350 | (2) |
|
|
352 | (4) |
|
choline magnesium trisalicylate |
|
|
356 | (2) |
|
|
358 | (2) |
|
|
360 | (3) |
|
|
363 | (3) |
|
|
366 | (4) |
|
|
370 | (3) |
|
|
373 | (4) |
|
|
377 | (2) |
|
|
379 | (1) |
|
|
379 | (4) |
|
|
383 | (3) |
|
fentanyl transdermal system |
|
|
386 | (4) |
|
|
390 | (4) |
|
levorphanol tartrate opioid |
|
|
394 | (4) |
|
|
398 | (4) |
|
|
402 | (4) |
|
|
406 | (4) |
|
morphine-dextromethorphan |
|
|
410 | (3) |
|
|
413 | (5) |
|
|
418 | (30) |
|
|
424 | (2) |
|
diphenhydramine hydrochloride |
|
|
426 | (2) |
|
|
428 | (3) |
|
|
431 | (1) |
|
|
432 | (2) |
|
granisetron hydrochloride |
|
|
434 | (1) |
|
|
435 | (2) |
|
metoclopramide hydrochloride |
|
|
437 | (2) |
|
ondansetron hydrochloride |
|
|
439 | (1) |
|
|
440 | (2) |
|
|
442 | (1) |
|
promethazine hydrochloride |
|
|
443 | (2) |
|
|
445 | (1) |
|
|
446 | (2) |
|
|
448 | (9) |
|
|
450 | (1) |
|
|
451 | (2) |
|
|
453 | (4) |
|
|
457 | (60) |
|
|
458 | (3) |
|
amitriptyline hydrochloride |
|
|
461 | (2) |
|
|
463 | (4) |
|
|
467 | (1) |
|
|
468 | (4) |
|
|
472 | (3) |
|
desipramine hydrochloride |
|
|
475 | (3) |
|
|
478 | (3) |
|
|
481 | (3) |
|
|
484 | (3) |
|
|
487 | (3) |
|
|
490 | (3) |
|
|
493 | (3) |
|
nortriptyline hydrochloride |
|
|
496 | (3) |
|
|
499 | (3) |
|
|
502 | (2) |
|
|
504 | (3) |
|
|
507 | (3) |
|
|
510 | (3) |
|
|
513 | (4) |
Section 3 Complications |
|
517 | (210) |
|
|
518 | (14) |
|
|
521 | (2) |
|
|
523 | (2) |
|
|
525 | (2) |
|
|
527 | (2) |
|
|
529 | (3) |
|
|
532 | (170) |
|
|
538 | (1) |
|
|
538 | (3) |
|
|
541 | (4) |
|
|
545 | (3) |
|
|
548 | (4) |
|
carbenicillin indanyl sodium |
|
|
552 | (2) |
|
|
554 | (3) |
|
|
557 | (4) |
|
|
561 | (4) |
|
|
565 | (3) |
|
|
568 | (3) |
|
|
571 | (3) |
|
|
574 | (3) |
|
|
577 | (4) |
|
|
581 | (4) |
|
|
585 | (3) |
|
|
588 | (4) |
|
|
592 | (3) |
|
|
595 | (2) |
|
co-trimoxazole; trimethoprim and sulfamethoxazole |
|
|
597 | (4) |
|
demeclocycline hydrochloride |
|
|
601 | (3) |
|
|
604 | (3) |
|
|
607 | (3) |
|
|
610 | (3) |
|
imipenem/cilastatin sodium |
|
|
613 | (3) |
|
|
616 | (4) |
|
|
620 | (3) |
|
metronidazole hydrochloride |
|
|
623 | (3) |
|
|
626 | (4) |
|
|
630 | (3) |
|
|
633 | (3) |
|
|
636 | (3) |
|
|
639 | (4) |
|
quinupristin and dalfopristin |
|
|
643 | (2) |
|
|
645 | (4) |
|
tetracycline hydrochloride |
|
|
649 | (3) |
|
|
652 | (4) |
|
|
656 | (3) |
|
|
659 | (3) |
|
|
662 | (3) |
|
|
665 | (1) |
|
amphotericin B, amphotericin B lipid complex |
|
|
665 | (4) |
|
|
669 | (3) |
|
|
672 | (2) |
|
|
674 | (2) |
|
|
676 | (3) |
|
|
679 | (3) |
|
|
682 | (1) |
|
|
683 | (1) |
|
|
683 | (3) |
|
|
686 | (4) |
|
|
690 | (2) |
|
|
692 | (2) |
|
|
694 | (3) |
|
|
697 | (4) |
|
valacyclovir hydrochloride |
|
|
701 | (1) |
|
|
702 | (15) |
|
|
703 | (1) |
|
docusate calcium, docusate potassium, docusate sodium |
|
|
704 | (1) |
|
|
705 | (2) |
|
|
707 | (1) |
|
|
708 | (1) |
|
|
709 | (1) |
|
|
710 | (2) |
|
|
712 | (1) |
|
|
713 | (2) |
|
|
715 | (2) |
|
|
717 | (10) |
|
deodorized tincture of opium |
|
|
718 | (1) |
|
diphenoxylate hydrochloride and atropine |
|
|
719 | (1) |
|
|
720 | (1) |
|
|
721 | (2) |
|
|
723 | (4) |
Section 4 Polypharmacy |
|
727 | (7) |
|
|
728 | (6) |
Appendix I Controlling Occupational Exposure to Hazardous Drugs |
|
734 | (30) |
Appendix II National Cancer Institute Common Toxicity Criteria |
|
764 | (57) |
Index |
|
821 | |